Literature DB >> 35126546

Intravascular imaging and novel techniques to disrupt severely calcified lesions.

Chinmay Khandkar1,2,3, Sanjay Patel2,3,4, Keyvan Karimi Galougahi2,3,4.   

Abstract

Entities:  

Year:  2021        PMID: 35126546      PMCID: PMC8802648          DOI: 10.5114/aic.2021.112523

Source DB:  PubMed          Journal:  Postepy Kardiol Interwencyjnej        ISSN: 1734-9338            Impact factor:   1.426


× No keyword cloud information.
Advancing age and co-morbid conditions (e.g., diabetes and chronic kidney disease) predispose to significant coronary calcification, which is present in up to one third of patients with coronary artery disease [1]. During percutaneous coronary intervention, these heavily calcified segments can present significant challenges, portending higher risks of both immediate complications (e.g. flow-limiting stent edge dissection) and long-term unfavourable events (e.g. in-stent restenosis (ISR), stent thrombosis, and myocardial infarction) compared with non-calcified lesions. Adjunctive techniques such as rotational atherectomy (RA) and recently intravascular lithotripsy (IVL), used in conjunction with imaging technologies such as intravascular ultrasound (IVUS) and optical computed tomography (OCT), are often necessary in treating heavily calcified lesions. In this issue of the journal, 3 cases are presented that highlight the complexities of dealing with challenging calcified lesions during percutaneous coronary intervention (PCI). In the first case, RA was used to modify a severely calcified lesion in the right coronary artery (RCA) that was initially resistant to pre-dilation. The ROTABLATOR system (Boston Scientific), which is more than three decades old, utilises rotation of a front-cutting diamond-crusted burr to ablate rigid coronary calcium [2]. Interestingly, the authors in this case identified extensive dissection with OCT imaging when having difficulty with non-compliant (NC) balloon inflations after several runs of a 1.5 mm burr. As a result, they chose to use a scoring balloon rather than a larger burr to fracture the calcified plaque and allow successful deployment of drug eluting stents. OCT confirmed adequate stent expansion. This case highlights the importance of intracoronary imaging, which provided detailed lesion characterisation for planning of the percutaneous intervention. One important point to highlight is that intracoronary imaging ought to be used upfront when assessing heavily calcified lesions to comprehensively assess the calcium morphology, and thus predict the likelihood of adequate stent expansion, and whether atherectomy devices would be required [1]. This is achieved with OCT by characterising the morphology of calcium deposits as deep, superficial, or nodular. A calcium score is subsequently calculated, which accounts for variables including calcium thickness, angle, and length. A score of ≥ 3 predicts the need for calcium modification prior to stent deployment, in order to reduce the risk of stent under-expansion. As depicted in Figure 1, this algorithmic approach is our preferred strategy to treat moderate to severely calcified lesions.
Figure 1

An algorithmic approach for complex calcified lesions. Adapted from Karimi Galougahi et al with permission.

*Calcium thickness can only be assessed by optical computed tomography (OCT). IVUS – intravascular ultrasound, NC – non-compliant, IVL – intravascular lithotripsy, OA – orbital atherectomy, RA – rotational atherectomy, DES – drug eluting stent.

An algorithmic approach for complex calcified lesions. Adapted from Karimi Galougahi et al with permission. *Calcium thickness can only be assessed by optical computed tomography (OCT). IVUS – intravascular ultrasound, NC – non-compliant, IVL – intravascular lithotripsy, OA – orbital atherectomy, RA – rotational atherectomy, DES – drug eluting stent. In the aforementioned case, the authors avoided using a larger burr with RA due to extensive proximal dissection detected on OCT after atherectomy and NC balloon dilatations. Whilst it is not unreasonable to use alternative modalities such as scoring balloons as in this case, the presence of dissection on OCT is not necessarily an absolute contraindication to further RA. As long as wire position remains in the true lumen, RA can be cautiously applied to safely complete the procedure [3]. Moreover, non-obstructive residual dissections after PCI detected on OCT only were not associated with major adverse cardiac events or late angiographic/clinical outcomes [4]. It is worth noting that both scoring balloons and NC balloons still pose a risk of dissection when employed to modify calcific plaque [5]. The second case involved the use of IVL under OCT guidance to treat ISR in the setting of incompletely expanded previous stents at the aorto-ostial segment. Stent under-expansion is a common cause of ISR, implicated in up to 55% of ISR lesions [1]. IVL delivers sonic pressure waves to fracture calcified plaque, thus increasing lesion compliance and allowing for adequate dilatation of the target lesion [6]. This in turn allows for optimal stent expansion [7]. The authors used IVL to facilitate better expansion, and subsequently used a drug-eluting balloon to deliver an antiproliferative drug. The use of IVL in freshly deployed drug-eluting stents (< 3 months from deployment) is not recommended as the shockwaves may damage the stent polymer and lead to incomplete release of the drug [7]. The use of a drug-eluting balloon in this context thus has a plausible rationale. The authors used OCT after the intervention to assess the final result, but again we recommend also using OCT upfront to identify both the extent and aetiology of stent under-expansion and assess for post-IVL fracturing of deep calcium to ensure optimal stent expansion. This step is especially important in this case involving the ostium of the RCA, which is known to be associated with lower procedural success due to marked elastic recoil and neointimal proliferation after balloon expansion [8]. Moreover, the OCT sub-study analysis in Disrupt CAD II [9] suggested that initial assessment with OCT may result in fewer angiographic complications although the differences were not statistically significant. The main advantage of using IVL in the cases of ISR is that it is not affected by the metal scaffolding from the under-expanded stents [7]. Other atherectomy devices such as RA are off-label use and pose the risk of entrapment in the stent struts or vessel perforation. Whilst case series on this relatively novel application of IVL are promising, future trials are required to validate the efficacy and safety of this approach to treating ISR [10]. IVL use in recently implanted (< 3 months) under-expanded stents may affect the integrity of the drug polymer coating and increase the risk of ISR due to neointimal proliferation [10]. Whether this risk actually exists and whether the use of drug-eluting balloons can mitigate the risk warrant further studies. The third case report presents the use of IVL in the setting of recurrent restenosis of an underexpanded stent in a saphenous vein graft (SVG) supplying a second marginal (OM2) artery. The ISR occurred despite multiple balloon angioplasties in previous years with a drug coated balloon. The authors achieved adequate post-dilation with an NC balloon after 80 cycles of shockwaves from IVL. Whilst the use of IVL in this setting remains off-label, it has significant advantages over atherectomy techniques such as RA, which poses much higher risks of perforation and distal embolization [7]. The authors highlight that the SVG supplied a relatively large area of myocardium. Given the well-documented increase in risk of no-reflow with PCI on SVG, one could consider the concurrent use of embolic protection devices to avoid potentially jeopardising the large area of the subtended myocardium in this case [11]. As in the previous cases, we also promote the adjunct use of intracoronary imaging for procedure planning and to confirm optimal stent expansion. The advent of new percutaneous techniques with high resolution intracoronary imaging has provided the opportunity to approach treatment of heavily calcified lesions known to be high risk of peri-procedural complication. These cases highlight how RA and IVL can be used to good effect in complex cases and provide clinicians with alternative strategies when faced with these challenges.

Conflict of interest

The authors declare no conflict of interest.
  11 in total

1.  Outcome of nonobstructive residual dissections detected by intravascular ultrasound following percutaneous coronary intervention.

Authors:  Takahiro Nishida; Antonio Colombo; Carlo Briguori; Goran Stankovic; Remo Albiero; Nicola Corvaja; Leo Finci; Carlo Di Mario; Jonathan M Tobis
Journal:  Am J Cardiol       Date:  2002-06-01       Impact factor: 2.778

2.  Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II Study.

Authors:  Ziad A Ali; Holger Nef; Javier Escaned; Nikos Werner; Adrian P Banning; Jonathan M Hill; Bernard De Bruyne; Matteo Montorfano; Thierry Lefevre; Gregg W Stone; Aaron Crowley; Mitsuaki Matsumura; Akiko Maehara; Alexandra J Lansky; Jean Fajadet; Carlo Di Mario
Journal:  Circ Cardiovasc Interv       Date:  2019-09-25       Impact factor: 6.546

3.  North American Expert Review of Rotational Atherectomy.

Authors:  Samin K Sharma; Matthew I Tomey; Paul S Teirstein; Annapoorna S Kini; Arthur B Reitman; Arthur C Lee; Philippe Généreux; Jeffrey W Chambers; Cindy L Grines; Stevan I Himmelstein; Craig A Thompson; Ian T Meredith; Aparna Bhave; Jeffrey W Moses
Journal:  Circ Cardiovasc Interv       Date:  2019-05       Impact factor: 6.546

4.  High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial.

Authors:  Mohamed Abdel-Wahab; Gert Richardt; Heinz Joachim Büttner; Ralph Toelg; Volker Geist; Thomas Meinertz; Joachim Schofer; Lamin King; Franz-Josef Neumann; Ahmed A Khattab
Journal:  JACC Cardiovasc Interv       Date:  2012-12-19       Impact factor: 11.195

5.  Calcific Plaque Modification by Acoustic Shock Waves: Intravascular Lithotripsy in Coronary Interventions.

Authors:  Keyvan Karimi Galougahi; Sanjay Patel; Richard A Shlofmitz; Akiko Maehara; Dean J Kereiakes; Jonathan M Hill; Gregg W Stone; Ziad A Ali
Journal:  Circ Cardiovasc Interv       Date:  2020-09-10       Impact factor: 6.546

6.  Management of stent underexpansion using intravascular lithotripsy-Defining the utility of a novel device.

Authors:  Julian Yeoh; Daan Cottens; Claudia Cosgrove; Khaled Mallek; Julian Strange; Richard Anderson; Simon Wilson; Colm Hanratty; Simon Walsh; Margaret McEntegart; Jonathan Hill; James C Spratt
Journal:  Catheter Cardiovasc Interv       Date:  2020-01-08       Impact factor: 2.692

Review 7.  Therapeutic Approach to Calcified Coronary Lesions: Disruptive Technologies.

Authors:  Keyvan Karimi Galougahi; Evan Shlofmitz; Allen Jeremias; Shawnbir Gogia; Ajay J Kirtane; Jonathan M Hill; Dimitri Karmpaliotis; Gary S Mintz; Akiko Maehara; Gregg W Stone; Richard A Shlofmitz; Ziad A Ali
Journal:  Curr Cardiol Rep       Date:  2021-03-05       Impact factor: 2.931

Review 8.  Embolic protection devices in saphenous vein graft and native vessel percutaneous intervention: a review.

Authors:  Eron Sturm; David Goldberg; Sheldon Goldberg
Journal:  Curr Cardiol Rev       Date:  2012-08

9.  Cutting-balloon angioplasty before drug-eluting stent implantation for the treatment of severely calcified coronary lesions.

Authors:  Zhe Tang; Jing Bai; Shao-Ping Su; Yu Wang; Mo-Han Liu; Qi-Cai Bai; Jin-Wen Tian; Qiao Xue; Lei Gao; Chun-Xiu An; Xiao-Juan Liu
Journal:  J Geriatr Cardiol       Date:  2014-03       Impact factor: 3.327

Review 10.  Contemporary Approach to Heavily Calcified Coronary Lesions.

Authors:  Carlotta Sorini Dini; Giulia Nardi; Francesca Ristalli; Alessio Mattesini; Brunilda Hamiti; Carlo Di Mario
Journal:  Interv Cardiol       Date:  2019-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.